Skip to content
2000
image of Single-Cell and Bulk Transcriptomic Integration Reveals a Stemness-Related Astrocyte Subpopulation for Prognostic Risk Stratification in Glioblastoma

Abstract

Introduction

Glioblastoma (GBM) is an aggressive brain tumor with pronounced heterogeneity. Stemness-related cell subpopulations are crucial for progression and therapy resistance, but their prognostic role remains unclear.

Methods

We integrated single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data to identify a stemness-high astrocyte subpopulation. Key genes were selected to construct a prognostic risk model using Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression, which was validated in The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) cohorts. Tumor microenvironment and pathway analyses were performed. functional assays were conducted on GBM cell lines.

Results

A four-gene signature ( and ) was established. The risk model robustly stratified patients into high- and low-risk groups with distinct overall survival in both cohorts. Importantly, multivariate Cox regression confirmed the RiskScore as an independent prognostic factor beyond age and isocitrate dehydrogenase (IDH) mutation status. Functional validation revealed that knockdown significantly suppressed GBM cell proliferation and migration . Further analyses showed that high-risk tumors were characterized by elevated immune/stromal scores, immunosuppressive cell infiltration, and activation of stemness-related pathways, including EGFR/MAPK, NF-κB, and VEGF-mediated angiogenesis.

Discussion

This integrated analysis identified a stemness-associated astrocyte subpopulation in GBM. The four-gene signature provides an independent prognostic tool and reflects immune microenvironment remodeling, offering insights into risk stratification and potential targeted therapy.

Conclusion

We developed a stemness-associated four-gene signature that enables risk stratification in GBM and reveals an immunosuppressive microenvironment in high-risk tumors, providing new directions for prognosis and targeted therapy.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673451085260213110913
2026-04-06
2026-04-17

  • From This Site

    /content/journals/cmc/10.2174/0109298673451085260213110913
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Lv G. Li X. Deng H. Zhang J. Gao X. Regulatory mechanisms of STAT3 in GBM and its impact on TMZ resistance. Curr. Mol. Pharmacol. 2025 17 18761429386400 10.2174/0118761429386400250415053351 40353463
    [Google Scholar]
  2. Yabo Y.A. Heiland D.H. Understanding glioblastoma at the single-cell level: Recent advances and future challenges. PLoS Biol. 2024 22 5 3002640 10.1371/journal.pbio.3002640 38814900
    [Google Scholar]
  3. Li J. Zhang Y. Liang C. Yan X. Hui X. Liu Q. Advancing precision medicine in gliomas through single-cell sequencing: Unveiling the complex tumor microenvironment. Front. Cell Dev. Biol. 2024 12 1396836 10.3389/fcell.2024.1396836 39156969
    [Google Scholar]
  4. Abdelrahman Z. Abdelatty A. Luo J. McKnight A.J. Wang X. Stratification of glioma based on stemness scores in bulk and single-cell transcriptomes. Comput. Biol. Med. 2024 175 108304 10.1016/j.compbiomed.2024.108304 38663352
    [Google Scholar]
  5. Louis D.N. Perry A. Wesseling P. Brat D.J. Cree I.A. Figarella-Branger D. Hawkins C. Ng H.K. Pfister S.M. Reifenberger G. Soffietti R. von Deimling A. Ellison D.W. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-oncol. 2021 23 8 1231 1251 10.1093/neuonc/noab106 34185076
    [Google Scholar]
  6. Hegi M.E. Diserens A.C. Gorlia T. Hamou M.F. de Tribolet N. Weller M. Kros J.M. Hainfellner J.A. Mason W. Mariani L. Bromberg J.E.C. Hau P. Mirimanoff R.O. Cairncross J.G. Janzer R.C. Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005 352 10 997 1003 10.1056/NEJMoa043331 15758010
    [Google Scholar]
  7. Shapovalov V. Kopanitsa L. Pruteanu L.L. Ladds G. Bailey D.S. Transcriptomics-based phenotypic screening supports drug discovery in human glioblastoma cells. Cancers 2021 13 15 3780 10.3390/cancers13153780 34359681
    [Google Scholar]
  8. Pruteanu L.L. Kopanitsa L. Módos D. Kletnieks E. Samarova E. Bender A. Gomez L.D. Bailey D.S. Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells. PLoS One 2020 15 9 0239551 10.1371/journal.pone.0239551 32946518
    [Google Scholar]
  9. Wang Z. Wang Y. Yang T. Xing H. Wang Y. Gao L. Guo X. Xing B. Wang Y. Ma W. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief. Bioinform. 2021 22 5 bbab032 10.1093/bib/bbab032 33839757
    [Google Scholar]
  10. Lee H. Kim B. Park J. Park S. Yoo G. Yum S. Kang W. Lee J.M. Youn H. Youn B. Cancer stem cells: Landscape, challenges and emerging therapeutic innovations. Signal Transduct. Target. Ther. 2025 10 1 248 10.1038/s41392‑025‑02360‑2 40759634
    [Google Scholar]
  11. Liu Y. Zhang S. Liu K. Hu X. Gu X. Advances in drug discovery based on network pharmacology and omics technology. Curr. Pharm. Anal. 2024 21 1 33 43 10.1016/j.cpan.2024.12.002
    [Google Scholar]
  12. He J. Yan X. Hu S. Glioma stem cells: Drivers of tumor progression and recurrence. Stem Cell Res. Ther. 2025 16 1 293 10.1186/s13287‑025‑04352‑z 40483525
    [Google Scholar]
  13. Singh S.K. Clarke I.D. Terasaki M. Bonn V.E. Hawkins C. Squire J. Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003 63 18 5821 5828 14522905
    [Google Scholar]
  14. Lu C. Kang T. Zhang J. Yang K. Liu Y. Song K. Lin Q. Dixit D. Gimple R.C. Zhang Q. Shi Z. Fan X. Wu Q. Li D. Shan D. Gao J. Gu D. You H. Li Y. Yang J. Zhao L. Qiu Z. Yang H. Zhao N. Gao W. Tao W. Lu Y. Chen Y. Ji J. Zhu Z. Kang C. Man J. Agnihotri S. Wang Q. Lin F. Qian X. Mack S.C. Hu Z. Li C. Taylor M.D. Liu N. Zhang N. Lu M. You Y. Rich J.N. Zhang W. Wang X. Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. Nat. Commun. 2025 16 1 2974 10.1038/s41467‑025‑58366‑5 40140646
    [Google Scholar]
  15. Visioli A. Trivieri N. Mencarelli G. Giani F. Copetti M. Palumbo O. Pracella R. Cariglia M.G. Barile C. Mischitelli L. Soriano A.A. Palumbo P. Legnani F. DiMeco F. Gorgoglione L. Pesole G. Vescovi A.L. Binda E. Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies. J. Exp. Clin. Cancer Res. 2023 42 1 244 10.1186/s13046‑023‑02811‑0 37735434
    [Google Scholar]
  16. Chen J. Li Y. Yu T.S. McKay R.M. Burns D.K. Kernie S.G. Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012 488 7412 522 526 10.1038/nature11287 22854781
    [Google Scholar]
  17. Sofroniew M.V. Vinters H.V. Astrocytes: Biology and pathology. Acta. Neuropathol. 2010 119 1 7 35 10.1007/s00401‑009‑0619‑8 20012068
    [Google Scholar]
  18. Nowacka A. Śniegocki M. Smuczyński W. Bożiłow D. Ziółkowska E. Angiogenesis in glioblastoma—Treatment approaches. Cells 2025 14 6 407 10.3390/cells14060407 40136656
    [Google Scholar]
  19. Zhang H. Zhou Y. Cui B. Liu Z. Shen H. Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma. Biomed. Pharmacother 2020 126 110086 10.1016/j.biopha.2020.110086
    [Google Scholar]
  20. Henrik Heiland D. Ravi V.M. Behringer S.P. Frenking J.H. Wurm J. Joseph K. Garrelfs N.W.C. Strähle J. Heynckes S. Grauvogel J. Franco P. Mader I. Schneider M. Potthoff A.L. Delev D. Hofmann U.G. Fung C. Beck J. Sankowski R. Prinz M. Schnell O. Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat. Commun. 2019 10 1 2541 10.1038/s41467‑019‑10493‑6 31186414
    [Google Scholar]
  21. Pantazopoulou V. Jeannot P. Rosberg R. Berg T.J. Pietras A. Hypoxia-induced reactivity of tumor-associated astrocytes affects glioma cell properties. Cells 2021 10 3 613 10.3390/cells10030613 33802060
    [Google Scholar]
  22. Zhang Y. Lv P. Zhang Q. Xiang W. Jiang X. Guo Z. Zhang T. Exosomal miR-21-5p from glioma associated mesenchymal stem cells promotes the progression and glycolysis of glioblastoma via PDHA1. Sci. Rep. 2025 15 1 2320 10.1038/s41598‑025‑86580‑0 39833311
    [Google Scholar]
  23. Dai J. Jiang Y. Hu H. Zhang S. Chen Y. Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment. Pathol. Oncol. Res. 2024 30 1611549 10.3389/pore.2024.1611549 38379858
    [Google Scholar]
  24. Tong M. Tu Q. Wang L. Chen H. Wan X. Xu Z. Joint analysis of single-cell RNA sequencing and bulk transcriptome reveals the heterogeneity of the urea cycle of astrocytes in glioblastoma. Neurobiol. Dis. 2025 208 106835 10.1016/j.nbd.2025.106835 39938577
    [Google Scholar]
  25. García-Vicente L. Martínez-Fernández M. Borja M. Tran V. Álvarez-Vázquez A. Flores-Hernández R. Ding Y. González-Sánchez R. Granados A. McGeever E. Kim Y.J. Detweiler A. Mekonen H. Paul S. Pisco A.O. Neff N.F. Tabernero A. Single-nucleus RNA sequencing reveals a preclinical model for the most common subtype of glioblastoma. Commun. Biol. 2025 8 1 671 10.1038/s42003‑025‑08092‑x 40295632
    [Google Scholar]
  26. Chen G. Ning B. Shi T. Single-cell RNA-Seq technologies and related computational data analysis. Front. Genet. 2019 10 317 10.3389/fgene.2019.00317 31024627
    [Google Scholar]
  27. Tan Z. Chen X. Zuo J. Fu S. Wang H. Wang J. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. J. Transl. Med. 2023 21 1 223 10.1186/s12967‑023‑04056‑z 36973787
    [Google Scholar]
  28. Wang J. Song Y. Li Z. Gao T. Shen W. Kang Z. Xu C. Combining single-cell and bulk RNA sequencing to identify CAF-related signature for prognostic prediction and treatment response in patients with melanoma. Sci. Rep. 2025 15 1 29082 10.1038/s41598‑025‑14979‑w 40781483
    [Google Scholar]
  29. Zhong C. Yang D. Zhong L. Xie W. Sun G. Jin D. Li Y. Single-cell and bulk RNA sequencing reveals Anoikis related genes to guide prognosis and immunotherapy in osteosarcoma. Sci. Rep. 2023 13 1 20203 10.1038/s41598‑023‑47367‑3 37980450
    [Google Scholar]
  30. Hao Y. Hao S. Andersen-Nissen E. Mauck W.M. III Zheng S. Butler A. Lee M.J. Wilk A.J. Darby C. Zager M. Hoffman P. Stoeckius M. Papalexi E. Mimitou E.P. Jain J. Srivastava A. Stuart T. Fleming L.M. Yeung B. Rogers A.J. McElrath J.M. Blish C.A. Gottardo R. Smibert P. Satija R. Integrated analysis of multimodal single-cell data. Cell 2021 184 13 3573 3587.e29 10.1016/j.cell.2021.04.048 34062119
    [Google Scholar]
  31. Korsunsky I. Millard N. Fan J. Slowikowski K. Zhang F. Wei K. Baglaenko Y. Brenner M. Loh P. Raychaudhuri S. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 2019 16 12 1289 1296 10.1038/s41592‑019‑0619‑0 31740819
    [Google Scholar]
  32. Gulati G.S. Sikandar S.S. Wesche D.J. Manjunath A. Bharadwaj A. Berger M.J. Ilagan F. Kuo A.H. Hsieh R.W. Cai S. Zabala M. Scheeren F.A. Lobo N.A. Qian D. Yu F.B. Dirbas F.M. Clarke M.F. Newman A.M. Single-cell transcriptional diversity is a hallmark of developmental potential. Science 2020 367 6476 405 411 10.1126/science.aax0249 31974247
    [Google Scholar]
  33. Aibar S. González-Blas C.B. Moerman T. Huynh-Thu V.A. Imrichova H. Hulselmans G. Rambow F. Marine J.C. Geurts P. Aerts J. van den Oord J. Atak Z.K. Wouters J. Aerts S. SCENIC: Single-cell regulatory network inference and clustering. Nat. Methods 2017 14 11 1083 1086 10.1038/nmeth.4463 28991892
    [Google Scholar]
  34. Song Z. Yu J. Wang M. Shen W. Wang C. Lu T. Shan G. Dong G. Wang Y. Zhao J. CHDTEPDB: Transcriptome expression profile database and interactive analysis platform for congenital heart disease. Congenit. Heart Dis. 2023 18 6 693 701 10.32604/chd.2024.048081
    [Google Scholar]
  35. Friedman J. Hastie T. Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 2010 33 1 1 22 10.18637/jss.v033.i01 20808728
    [Google Scholar]
  36. Jiang X. Li W. Wang K. Li R. Ning J. Analyzing heterogeneity in biomarker discriminative performance through partial time-dependent receiver operating characteristic curve modeling. Stat. Methods Med. Res. 2024 33 8 1424 1436 10.1177/09622802241262521 39053568
    [Google Scholar]
  37. Wu T. Hu E. Xu S. Chen M. Guo P. Dai Z. Feng T. Zhou L. Tang W. Zhan L. Fu X. Liu S. Bo X. Yu G. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2021 2 3 100141 10.1016/j.xinn.2021.100141 34557778
    [Google Scholar]
  38. Abiraamavalli T. Namasivayam S.K.R. In vitro formulation and potential biological activities of metabolites consortium with high biocompatibility derived from poly herbal plant extracts. Natl Acad Sci Lett 2025 10.1007/s40009‑025‑01656‑9
    [Google Scholar]
  39. Aswinanand B. Balakrishnan J. Kumaradoss K.M. Almutairi M.H. Almutairi B.O. Raja Namasivayam S.K. Palaniappan S. Arockiaraj J. Thiazol-sulfonyl derivative KM9 mitigates hyperglycemia-associated steatotic liver injury in in-vitro and in-vivo models. Med. Microecology 2025 26 100151 10.1016/j.medmic.2025.100151
    [Google Scholar]
  40. Schubert M. Klinger B. Klünemann M. Sieber A. Uhlitz F. Sauer S. Garnett M.J. Blüthgen N. Saez-Rodriguez J. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 2018 9 1 20 10.1038/s41467‑017‑02391‑6 29295995
    [Google Scholar]
  41. Ye Z. Yuan J. Yi Q. Xu P. Liu W. SNP rs615552 and lncRNA CDKN2B-AS1 influence brain cancer pathogenesis through multi-omic mechanisms. Sci. Rep. 2025 15 1 27490 10.1038/s41598‑025‑10360‑z 40721593
    [Google Scholar]
  42. Wang J. Li J. Peng J. Zhang C. Chen Z. Miao C. Tang C. Luo Q. COL8A1 as a pro-inflammatory mediator bridges immune evasion and therapy resistance in glioma. Front. Immunol. 2025 16 1727298 10.3389/fimmu.2025.1727298
    [Google Scholar]
  43. Song J. Li H. Liu Y. Li X. Shi Q. Lei Q.Y. Hu W. Huang S. Chen Z. He X. Aldolase A. Aldolase A accelerates cancer progression by modulating mRNA translation and protein biosynthesis via noncanonical mechanisms. Adv. Sci. 2023 10 26 2302425 10.1002/advs.202302425 37431681
    [Google Scholar]
  44. Wang Y. Tang J. Liu Y. Zhang Z. Zhang H. Ma Y. Wang X. Ai S. Mao Y. Zhang P. Chen S. Li J. Gao Y. Cheng C. Li C. Su S. Lu R. Targeting ALDOA to modulate tumorigenesis and energy metabolism in retinoblastoma. iScience 2024 27 9 110725 10.1016/j.isci.2024.110725 39262779
    [Google Scholar]
  45. Tian W. Zhou J. Chen M. Qiu L. Li Y. Zhang W. Guo R. Lei N. Chang L. Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity. Sci. Rep. 2022 12 1 11632 10.1038/s41598‑022‑15866‑4 35804089
    [Google Scholar]
  46. George Warren W. Osborn M. Yates A. Wright K. O’Sullivan S.E. The emerging role of fatty acid binding protein 5 (FABP5) in cancers. Drug Discov. Today 2023 28 7 103628 10.1016/j.drudis.2023.103628 37230284
    [Google Scholar]
  47. Tang Q. Mao X. Chen Z. Ma C. Tu Y. Zhu Q. Lu J. Wang Z. Zhang Q. Wu W. Liquid–liquid phase separation-related gene in gliomas: FABP5 is a potential prognostic marker. J. Gene Med. 2023 25 10 3517 10.1002/jgm.3517 37114595
    [Google Scholar]
  48. Duman C. Di Marco B. Nevedomskaya E. Ulug B. Lesche R. Christian S. Alfonso J. Targeting fatty acid oxidation via Acyl-CoA binding protein hinders glioblastoma invasion. Cell Death Dis. 2023 14 4 296 10.1038/s41419‑023‑05813‑0 37120445
    [Google Scholar]
  49. Liu L. Yang S. Lin K. Yu X. Meng J. Ma C. Wu Z. Hao Y. Chen N. Ge Q. Gao W. Wang X. Lam E.W.F. Zhang L. Li F. Jin B. Jin D. Sp1 induced gene TIMP1 is related to immune cell infiltration in glioblastoma. Sci. Rep. 2022 12 1 11181 10.1038/s41598‑022‑14751‑4 35778451
    [Google Scholar]
  50. Xu J. Wei C. Wang C. Li F. Wang Z. Xiong J. Zhou Y. Li S. Liu X. Yang G. Han L. Zhang J. Zhang S. TIMP1/CHI3L1 facilitates glioma progression and immunosuppression via NF-κB activation. Biochim. Biophys. Acta Mol. Basis Dis. 2024 1870 3 167041 10.1016/j.bbadis.2024.167041 38290591
    [Google Scholar]
  51. Guo F. Ling G. Zhai Z. Lei Y. Mo L. Piao H. Identification and validation of prognostic genes and immune landscape signatures based on a fatty acid oxidation‑related risk score model in glioma. Oncol. Lett. 2024 27 2 88 10.3892/ol.2024.14222 38249808
    [Google Scholar]
  52. Masiulionytė B. Valiulytė I. Tamašauskas A. Skiriutė D. Metallothionein genes are highly expressed in malignant astrocytomas and associated with patient survival. Sci. Rep. 2019 9 1 5406 10.1038/s41598‑019‑41974‑9 30932010
    [Google Scholar]
  53. Franceschi S. Lessi F. Aretini P. Ortenzi V. Scatena C. Menicagli M. La Ferla M. Civita P. Zavaglia K. Scopelliti C. Apollo A. Carbone F.G. Vannozzi R. Bevilacqua G. Pasqualetti F. Naccarato A.G. Mazzanti C.M. Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: New emerging cancer players. Oncotarget 2018 9 35 24014 24027 10.18632/oncotarget.25265 29844869
    [Google Scholar]
  54. Tataranu L.G. Turliuc S. Kamel A. Rizea R.E. Dricu A. Staicu G.A. Baloi S.C. Rodriguez S.M.B. Manole A.I.M. Glioblastoma tumor microenvironment: An important modulator for tumoral progression and therapy resistance. Curr. Issues Mol. Biol. 2024 46 9 9881 9894 10.3390/cimb46090588 39329940
    [Google Scholar]
  55. Tao Y. Zhu J. Yu X. Cong H. Li J. Cai T. Chen Q. Prognostic risk of immune-associated signature in the microenvironment of brain gliomas. Front. Genet. 2023 14 1208651 10.3389/fgene.2023.1208651 37867596
    [Google Scholar]
  56. Jiang A. Wang J. Liu N. Zheng X. Li Y. Ma Y. Zheng H. Chen X. Fan C. Zhang R. Fu X. Yao Y. Integration of single-cell RNA sequencing and bulk RNA sequencing data to establish and validate a prognostic model for patients with lung adenocarcinoma. Front. Genet. 2022 13 833797 10.3389/fgene.2022.833797 35154287
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673451085260213110913
Loading
Single-Cell and Bulk Transcriptomic Integration Reveals a Stemness-Related Astrocyte Subpopulation for Prognostic Risk Stratification in Glioblastoma
Bentham Science Publishers ; https://doi.org/10.2174/0109298673451085260213110913
/content/journals/cmc/10.2174/0109298673451085260213110913
/content/journals/cmc/10.2174/0109298673451085260213110913
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: astrocytes ; Glioblastoma ; single-cell RNA sequencing ; prognostic model ; tumor microenvironment ; stemness

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test